Replies to post #211107 on Biotech Values

[biomaven0]

>>TRIL

Platelets subvert T cell immunity against cancer via GARP-TGFß axis <<

The dose-limiting AE isn't a bug, it's a feature. :)

[mcbio]

TRIL/ARGX -

Platelets subvert T cell immunity against cancer via GARP-TGFß axis

The reference to GARP is interesting to me as I'm long both TRIL and argenx (ARGX.BR). ARGX is partnered with ABBV on ARGX-115, which targets GARP.

Here's a recent PR noting the $10M ARGX received from ABBV just for achieving the first of two pre-clinical milestones: http://www.argen-x.com/en-GB/news-internal/argenx-receives-first-preclinical-milestone-payment-in-abbvie-collaboration/10140/ . From that PR:

"ARGX-115 employs argenx’s SIMPLE Antibody™ technology and works by stimulating a patient’s immune system after a tumor has suppressed the immune system by co-opting immunosuppressive cells such as activated regulatory T-cells (Tregs). While the normal function of Tregs is to suppress portions of the immune system to prevent a self-directed immune response through the release of active transforming growth factor beta (TGF-ß), Tregs can also prevent the immune system from recognizing and suppressing pathogenic cells including cancer cells. By binding to glycoprotein A repetitions predominant (GARP), which plays a key role in the regulation of production and release of active TGF-ß, ARGX-115 works to limit the immunosuppressive activity of Tregs and thereby stimulate the immune system to attack cancer cells. We believe this specific inhibition of TGF-ß release by Tregs is potentially superior as a therapy to systemic inhibition of TGF-ß activity or the depletion of Tregs with a potentially improved safety profile."

Here's the original PR from last year related to the deal with ABBV: http://www.argen-x.com/en-GB/news-internal/argenx-and-abbvie-to-collaborate-on-argx-115-against-novel-immuno-oncology-target/109/ . ARGX got $40M up-front, can receive up to double-digit royalties, and retained the right to co-promote the drug in the EU and Swiss Economic Area.

[semi_infinite]

Aspirin?

[DFRAI]

Tril - Platelets

So cancer can use Platelets to decrease Tcell functions of killing cancer

1. another avoidance/escape mechanism that cancer uses

Not sure why TRIL was referenced by you

2. How is this good for TRIL? or bad?